BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19718051)

  • 1. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.
    Gruhne B; Sompallae R; Masucci MG
    Oncogene; 2009 Nov; 28(45):3997-4008. PubMed ID: 19718051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma.
    Kamranvar SA; Gruhne B; Szeles A; Masucci MG
    Oncogene; 2007 Aug; 26(35):5115-23. PubMed ID: 17325665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.
    Leao M; Anderton E; Wade M; Meekings K; Allday MJ
    J Virol; 2007 Jan; 81(1):248-60. PubMed ID: 17035311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication.
    Van Scoy S; Watakabe I; Krainer AR; Hearing J
    Virology; 2000 Sep; 275(1):145-57. PubMed ID: 11017796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of expression of insulin and IGF-I receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines.
    Kriauciunas KM; Goldstein BJ; Lipes MA; Kahn CR
    J Cell Physiol; 1993 Mar; 154(3):486-95. PubMed ID: 8382208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
    Doyle MG; Crawford DH
    Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
    Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
    Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1.
    Zhang L; Pagano JS
    J Virol; 2000 Feb; 74(3):1061-8. PubMed ID: 10627515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells.
    Allday MJ; Crawford DH; Thomas JA
    J Gen Virol; 1993 Mar; 74 ( Pt 3)():361-9. PubMed ID: 8383171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection.
    Contreras-Salazar B; Ehlin-Henriksson B; Klein G; Masucci MG
    J Virol; 1990 Nov; 64(11):5441-7. PubMed ID: 2170681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block.
    Choudhuri T; Verma SC; Lan K; Murakami M; Robertson ES
    J Virol; 2007 Jun; 81(12):6718-30. PubMed ID: 17409144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
    Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
    Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked, transient inhibition of expression of the Epstein-Barr virus latent membrane protein gene in Burkitt's lymphoma cell lines by electroporation.
    Gahn TA; Sugden B
    J Virol; 1993 Nov; 67(11):6379-86. PubMed ID: 8411339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latent membrane protein 1 of Epstein-Barr virus plays an important role in the serum starvation resistance of Epstein-Barr virus-immortalized B lymphocytes.
    Park CH; Kim HR; Kim J; Jang SH; Lee KY; Chung GH; Jang YS
    J Cell Biochem; 2004 Mar; 91(4):777-85. PubMed ID: 14991769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
    Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
    J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
    Kennedy G; Komano J; Sugden B
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter.
    Jiménez-Ramírez C; Brooks AJ; Forshell LP; Yakimchuk K; Zhao B; Fulgham TZ; Sample CE
    J Virol; 2006 Nov; 80(22):11200-8. PubMed ID: 16956945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.